{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-040809","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.062279+00:00","generated_at":"2026-05-22T03:38:47.822937+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protara Therapeutics Q1 2025 net loss $11.9M; TARA-002 100% CR in BCG-Unresponsive cohort","bullets":["Cash, cash equivalents and investments total $157.5M as of Mar 31, 2025; expected to fund operations into 2027.","TARA-002 in BCG-Unresponsive NMIBC: 100% complete response (CR) at any time (5/5), 67% CR at 12 months (2/3) as of Apr 16, 2025.","Interim results from ~25 six-month evaluable BCG-Unresponsive patients expected by end of 2025; THRIVE-3 trial of IV Choline Chloride to start Q3 2025.","Appointed Leonardo Viana Nicacio, M.D., as CMO and Shane Williams, Ph.D., as VP, Head of HR/Chief People Officer in April 2025.","Net loss $11.9M ($0.29/sh) vs $11.1M ($0.97/sh) in Q1 2024; R&D expenses rose to $9.1M from $7.7M, G&A to $5.0M from $4.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-040809","json":"https://secwatch.observer/filing/0001213900-25-040809.json","markdown":"https://secwatch.observer/filing/0001213900-25-040809.md","text":"https://secwatch.observer/filing/0001213900-25-040809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025040809/0001213900-25-040809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025040809/ea0240929-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:38:47.822937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}